Antithrombotic strategies in patients undergoing percutaneous coronary intervention for acute coronary syndrome

Drug Design, Development and Therapy

Volumn 4, Issue , 2010, Pages 203-220

  Pham, Son V ^a   Pham, Phuong Chi T ^b   Pham, Phuong Mai T ^c   Miller, Jeffrey M ^b   Pham, Phuong Thum T ^d   Pham, Phuong Anh T ^e  

^a Bay Pines VA Medical Center   (United States)

^b OLIVE VIEW UCLA MEDICAL CENTER   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e Sutter General Hospital   (United States)

Author keywords

Acute coronary syndrome; Aspirin; Bivalirudin; Clopidogrel; Glycoprotein IIb IIIa inhibitors; Percutaneous coronary intervention

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; CANGRELOR; CLOPIDOGREL; ENOXAPARIN; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; FONDAPARINUX; HEPARIN; HIRULOG; PLACEBO; PRASUGREL; THIENOPYRIDINE DERIVATIVE; TICAGRELOR; TICLOPIDINE; TIROFIBAN; ANTITHROMBOCYTIC AGENT; DRUG DERIVATIVE; FIBRINOLYTIC AGENT;

ACUTE CORONARY SYNDROME; ADD ON THERAPY; AGRANULOCYTOSIS; APLASTIC ANEMIA; ARTICLE; BARE METAL STENT; BLEEDING; CATHETER THROMBOSIS; CHOLESTASIS; CONTINUOUS INFUSION; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; CORONARY STENT; CREATININE BLOOD LEVEL; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ELUTING STENT; DRUG ERUPTION; DRUG HALF LIFE; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; FIBRINOLYTIC THERAPY; HEART ARRHYTHMIA; HEART BUNDLE BRANCH BLOCK; HEART INFARCTION; HUMAN; LOADING DRUG DOSE; LONG TERM CARE; LOW DRUG DOSE; MAINTENANCE THERAPY; NEUTROPENIA; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; OUTCOME ASSESSMENT; PANCYTOPENIA; PERCUTANEOUS CORONARY INTERVENTION; RISK REDUCTION; SIDE EFFECT; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STROKE; THROMBOCYTE AGGREGATION; THROMBOCYTOPENIA; THROMBOTIC THROMBOCYTOPENIC PURPURA; UNSTABLE ANGINA PECTORIS; URIC ACID BLOOD LEVEL; CLINICAL TRIAL (TOPIC); METHODOLOGY; REVIEW; STENT; TRANSLUMINAL CORONARY ANGIOPLASTY;

ACUTE CORONARY SYNDROME; ANGIOPLASTY, BALLOON, CORONARY; ASPIRIN; CLINICAL TRIALS AS TOPIC; FIBRINOLYTIC AGENTS; HUMANS; PLATELET AGGREGATION INHIBITORS; STENTS; TICLOPIDINE;

EID: 79952053493     PISSN: 11778881     EISSN: None     Source Type: Journal    
DOI: 10.2147/DDDT.S12056     Document Type: Article

References (53)

1. Jolly SS, Pogue J, Haladyn K, et al. Effcets of asapirin dose on ischemic events and bleeding after percutaneous coronary intervention: insights from the PCI-CURE Study. Eur Heart J. 2009;30:900-907.
2. Mehta SR, Bassand JP, Chrolavicius S, et al. Design and rationale of CURRENT-OASIS 7: a randomized, 2 × 2 factorial trial evaluation optimal dosing strategies for clopidogrel and aspirin in patients with ST and non-ST-elevation acute coronary syndromes managed with an early invasive strategy. Am Heart J. 2008;156: 1080-1088.
3. Krumholz HM, Anderson JL, Bachelder BL, et al. ACC/AHA 2008 Performance Measures for Adults With ST-Elevation and Non-ST-Elevation Myocardial Infarction. A Report of the American College of Cardiology/ American Heart Association Task Force on Performance Measures. J Am Coll Cardiol. 2008;52:2046-2099.
4. Mehta SR, Yusuf S, Peters RJ, et al. Effects of pretreatment with clopidrogel and aspririn followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet. 2001;358:527-533.
5. Steinhubl SR, Berger PB, Mann JT, et al. Early and sustained dula oral antiplatelet therapy following percutaneous coronary intervention. JAMA. 2002;288:2411-2420.
6. Steinhubl SR, Berger PB, Brennan DM, et al. Optimal timing for the initiation of pretreatment with 300 mg clopidrogel before percutaneous coronary intervention. J Am Coll Cardiol. 2006;47:939-943.
7. Patti G, Colonna G, Pasceri V, et al. Randomized trial of high loading dose of clopidrogel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention: results from the ARMYDA-2 (Antiplatelet therapy for Reduction of Myocardial Damage during angioplasty) Study. Circulation. 2005;111: 2099-2106.
8. Triocco P, Harrington RA. Letters regarding Article by Patti et al. "Randomized trial of high loading dose of clopidrogel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention: results from the ARMYDA-2 (Antiplatelet therapy for Reduction of Myocardial Damage during angioplasty) Study". Circulation. 2005;112:e282.
9. Wolfram R, Torguson RL, Hassani S-E, et al. Clopidrogel loading dose (300 versus 600 mg) strategies for patients with stable angina pectoris subjected to percutaneous coronary intervention. Am J Cardiol. 2006;97: 984-989.
10. Lotrionte M, Biondi-Zoccai GGL, Agostoni P, et al. Meta-analysis appraising high Clopidrogel loading in patients undergoing percutaneous coronary intervention. Am J Cardiol. 2007;100: 1199-1206.
11. Kandzari DE, Berger PB, Kastrati A, et al. Influence of treatment duration with a 600-mg dose of clopidogrel before percutaneous coronary revascularization. J Am Coll Cardiol. 2004;44:2133-2136.
12. von Beckerath N, Taubert D, Pogatsa-Murray G, et al. Absorption, metabolism, and antiplatelet effects of 300-, 600-, and 900-mg loading doses of clopidogrel. Results of the ISAR-CHOICE (Intracoronary Stenting and Antithrombic Regimen: Choose Between 3 High Oral Doses for Immediate Clopidogrel Effect) Trial. 2005;112:2946-2950.
13. Brandt JT, Payne CD, Wiviott SD, et al. A comparison of prasugrel and clopidrogel loading dose on platelet function: Magnitude of platelet inhibition is related to active metabolite formation. Am Heart J. 2007; 153:66-69.
14. Wiviott SD, Braunwald E, McCabe C, et al. Prasugrel versus clopidrogel in patients with acute coronary syndromes. N Engl J Med. 2007;357: 2001-2015.
15. Montalescot G, Wiviott SD, Braunwald E, et al. Prasugrel compared with clopidrogel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): doubleblind, randomized controlled trial. Lancet. 2009;373:723-731.
16. A Comparison of Prasugrel and Clopidogrel in Acute Coronary Syndrome Subjects (TRILOGY ACS). This study is currently recruiting participants. ClinicalTrials.gov.
17. Kushner FG, Hand M, Smith SC Jr, et al. 2009 Focused Updates: ACC/ AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction (Updating the 2004 Guideline and 2007 Focused Update) and ACC/AHA/SCAI Guidelines on Percutaneous Coronary Intervention (Updating the 2005 Guideline and 2007 Focused Update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2009:120:2271-2306.
18. Husted S, Emanuelsson H, Heptinstall S, et al. Parmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonoist AZD6140 with aspirin in patients with atherosclerosis: a doubleblind comparison to clopidrogel with aspirin. Eur Heart J. 2006;27: 1038-1047.
19. Cannon CP, Hudsted S, Harrington A, et al. Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidrogel, in patients with non-ST segment elevation acute coronary syndrome: primary results of the DISPERSE-2 trial. J Am Coll Cardiol. 2007;50:1844-1851.
20. Wallentin L, Becker RC, Budaj A, et al, for the PLATO Investigators. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl Med J. 2009;361:1045-1057.
21. Angiolillo DJ, Bhatt DL, Gurbel PA, et al. Advances in antiplatelet therapy: agents in clinical development. Am J Cardiol. 2009;103: 40A-51A.
22. Bhatt DL, Lincoff AM, Gibson CM, et al; for the CHAMPION PLATFORM Investigators. Intravenous platelet blockade with cangrelor during PCI. N Eng J Med. 2009;361:2330-2341.
23. Harrington RA, Stone GW, McNulty S, et al. Platelet inhibition with cangrelor in patients undergoing PCI. N Engl J Med. 2009;361: 2318-2329.
24. Maintenance of Platelet Inhibition with Cangrelor (Bridge). This study is currently recruiting participants. ClinicalTrials.gov.
25. The TIMI IIIB Investigators. Effects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and non-Q-wave myocardial infarction: results of the TIMI IIIB trial. Circulation. 1994;89:1545-1556.
26. Boden WE, O'Rourke RA, Crawford MH, et al. Outcomes in patients with acute non-Q-wave myocardial infarction randomly assigned to an invasive as compared with a conservative management strategy. N Engl J Med. 1998;338:1785-1792.
27. McCullough PA, O'Neil WW, Graham M, et al. A prospective randomized trial of triage angiography in acute coronary syndromes ineligible for thrombotic therapy: results of the Medicine versus Angiography in Thrombolytic Exclusion (MATE) trial. J Am Coll Cardiol. 1998;32: 596-605.
28. Arora RR, Rai F, Rai F. Antiplatelet intervention in acute coronary syndrome. Am J Therapeutics. 2009;16,e29-e40.
29. Cannon CP, Weintraub WS, Demopoulos LA, et al. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein GIIb/IIIa inhibitor tirofiban. N Engl J Med. 2001;344:1879-1887.
30. Hoekstra JW, Roe MT, Peterson ED, et al. Early glycoprotein IIb/IIIa inhibitor use for non-ST-segment elevation acute coronary syndrome: patient selection and associated treatment patterns. Acad Emerg Med. 2005;12:431-437.
31. Topol GJ, Califf RM, Weissman HF, et al. Randomized trial of coronary intervention with antibody against platelet glycoprotein IIb/IIIa integrin for reduction of clinical restenosis: results at 6 months. The EPIC investigators. Lancet. 1994;343:1430-1435.
32. Montalescot G, Antoniucci D, Kastrati A, et al. Abciximab in primary coronary stenting of ST-elevation myocardial infarction: a European meta-analysis on individual patients' data with long-term follow up. European Heart J. 2007;28:443-449.
33. The Impact-II investigators. Randomized, placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention. Impact-II. Lancet. 1997;349;1422-1428.
34. O'Shea JC, Hafley GE, Greenberg S, et al. ESPRIT Investigators. Platelet GP IIb/IIIa integrin blockade with eptif ibatide in coronary stent intervention: the ESPRIT trial. JAMA. 2001;285: 2468-2473.
35. Topol EJ, Moliterno DJ, Herrmann HC, et al. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. N Engl Med J. 2001;344:1888-1894.
36. Van't Hof AW, Ten Berg J, Heetermans T, et al. Prehospital intiation of tirofiban in patients with ST-elevation myocardial infarction undergoing primary angioplasty (On-TIME) 2: a multicentre, double-blind, randomized controlled trial. Lancet. 2008;16372:537-546.
37. Valgimigli M, Campo G, Arcozzi C, et al. Comparison of angioplasty with infusion of tirofiban or abciximab and with implantation of sirolimus-eluting or uncoated stents for acute myocardioal infarction. The MULTISTRATEGY randomized trial. JAMA. 2008; DOI:10.1001/ jama.299.15.joc80026.
38. Labinaz M, Ho C, Banerjee S, et al. Meta-analysis of clinical efficacy and bleeding risk with intravenous glycoprotein IIb/IIIa antagonists for percutaneous coronary intervention. Can J Cardiol. 2007;23: 963-970.
39. White HD, Kleiman NS, Mahaffey KW, et al. Efficacy and safety of enoxaparin compared with unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention in the Superior Yield of the New Strategy of Enoxaparin, Revascularization and glycoprotein IIb/III ainhibitors (SYNERGY) trial. Am J Heart. 2006;152: 1042-1050.
40. STEMI Treated With Primary Angioplasty and Intravenous Lovenox or Unfractionated Heparin (UFH) (ATOLL). This study is currently recruiting participants. ClinicalTrials.gov.
41. Mehta SR, Steg PG, Granger CB, et al. Randomized, blinded trial comparing fondaparinux with unfractionated heparin in patients undergoing contemporary percutaneous coronary intervention. Arixtra Study in Percutaneous Coronary Intervention: a randomized evaluation (ASPIRE) pilot trial. Circulation. 2005;111:1390-1397.
42. The Oasis-6 Trial. Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction. The OASIS-6 Randomized Trial. JAMA. 2006;295(13): 1519-1530.
43. Mehta SR, Granger CB, Eikelboom JW, et al. Eff icacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: results from the OASIS-5 trial. J Am Coll Cardiol. 2009;50: 742-1751.
44. Bittl JA, Chaitman BR, Feit F, et al; for the Bivalirubin Angioplasty Study Investigators. Bivalirubin versus heparin during coronary angioplasty for unstable for postinfarction angina: final report reanalysis of the Bivalirubin Angioplasty Study. Am J Heart. 2001;142: 952-959.
45. Lincoff AM, Kleiman NS, Kottke-Marchant K, et al. Bivalirubin with planned or provisional abciximab versus low-dose heparin and abciximab during percutaneous coronary revascularization: results of the Comaprison of Abciximab Complications with Hirulog for Ischemic Events Trial (CACHET). Am J Heart. 2002;143: 847-853.
46. Lincoff AM, Bittl JA, Kleiman NS, et al. The REPLACE-1 Trial: comparison of bivalirubin versus heparin during percutaneous coronary intervention (The Randomized Evaluation of Percutaneous Coronary Intervention Linking Angiomax to Reduced Clinical Events [REPLACE]-1 trial. Am J Cardiol. 2004;93: 1092-1096.
47. White HD, Ohman EM, Lincoff AM, et al. Safety and efficacy of bivalirubin with and without glycoprotein IIb/IIIa inhibitors in patients with acute coronary syndromes undergoing percutaneous coronary intervention: 1-year results from the ACUITY (Acute Catheterization and Urgent Intervention Triage StartegY) trial. J Am Coll Cardiol. 2008;52:807-814.
48. Lincoff AM, Bittl JA, Harrington RA, et al. Bivalirubin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 Randomized Trial. JAMA. 2003;289(7):853-863.
49. Stone GW, Witzenbichler B, Guagliumi G, et al. Bivalirubin during primary PCI in acute myocardial infarction. N Engl Med J. 2008;358:2218-2230.
50. Angiolillo DJ, Guzman LA, Bass TA. Current antiplatelet therapies: benefits and limitations. Am Heart J. 2008;156:S3-S9.
51. Bassand JP. Bleeding and transfusion in acute coronary syndromes: a shift in the paradigm. Heart. 2008;94:661-666.
52. de Luca L, Casella G, Lettino M, et al. Clinical implications and management of bleeding events in patients with acute coronary syndromes. J Cardiovasc Med. 2009;10(9):677-686.
53. Alexander KP, Chen AY, Roe MT, et al. CRUSADE investigators. Excess dosing of antiplatelet and antithrombin agents in the treatment of non-ST-segment elevation acute coronary syndromes. JAMA. 2005;294: 3108-3116.